{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:21:51Z","timestamp":1761513711765},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s40261-015-0351-1","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T06:14:58Z","timestamp":1445926498000},"page":"87-91","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety of Overnight Switch from Brand-Name to Generic Levetiracetam"],"prefix":"10.1007","volume":"36","author":[{"given":"Maria Stella","family":"Vari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Mencaroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Giudizioso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Minetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"La Neve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Francavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Piccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Striano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"del Gaudio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierangelo","family":"Tovo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Striano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"key":"351_CR1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2165\/10898530-000000000-00000","volume":"70","author":"SA Kesselheim","year":"2010","unstructured":"Kesselheim SA, Stedman MR, Bubrick EJ, Gagne J, Misono A, Lee J, Bookhart A, Avorn J, Shrank W. Seizure outcome following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70:605\u201321.","journal-title":"Drugs"},{"key":"351_CR2","first-page":"81","volume":"15","author":"SJ Shaw","year":"2010","unstructured":"Shaw SJ, Hartman AL. The controversy over generic antiepileptic drugs. J Pediatr Pharmacol Ther. 2010;15:81\u201393.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"351_CR3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1212\/01.wnl.0000259400.30539.cc","volume":"68","author":"K Liow","year":"2007","unstructured":"Liow K, Barkley GL, Pollard JR, Harden CL, Bazil CW. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007;68:1249\u201350.","journal-title":"Neurology"},{"key":"351_CR4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/ana.22452","volume":"70","author":"GL Krauss","year":"2011","unstructured":"Krauss GL, Caffo B, Chang YT, et al. Assessing the BE of generic AEDs. Ann Neurol. 2011;70:221\u20138.","journal-title":"Ann Neurol"},{"key":"351_CR5","first-page":"520","volume":"71","author":"MJ Berg","year":"2008","unstructured":"Berg MJ, Gross RA, Tomaszewki KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008;71:520\u201330.","journal-title":"Neurology"},{"key":"351_CR6","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1212\/01.wnl.0000313154.55518.25","volume":"70","author":"J LeLorie","year":"2008","unstructured":"LeLorie J, Dhu MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70:2179\u201386.","journal-title":"Neurology"},{"key":"351_CR7","first-page":"CD001901","volume":"1","author":"R Chaisewikul","year":"2001","unstructured":"Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam addon for drug-resistant localization-related (partial) Epilepsy (cochrane review). Cochrane Database Syst Rev. 2001;1:CD001901.","journal-title":"Cochrane Database Syst Rev"},{"key":"351_CR8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1059-1311(03)00139-0","volume":"12","author":"GL Krauss","year":"2003","unstructured":"Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalized epilepsy. Seizure. 2003;12:617\u201320.","journal-title":"Seizure"},{"key":"351_CR9","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/epi.13030","volume":"56","author":"C Louni","year":"2015","unstructured":"Louni C, Canevini MP, Capovila G, De Sarro G, Galimberti CA, Gatti G, Guerrini R, La Neve A, Mazzucchelli I, Rosati E, Specchio LM, Striano S, Tinuper P, Perucca E, Study of Outcome of PHarmacoresistence In Epilepsy (SOPHIE) collaborators. A prospective study of direct medical costs in a large cohort of consecutively enrolled patients with refractory epilepsy in Italy. Epilepsia. 2015;56:1162\u201373.","journal-title":"Epilepsia"},{"key":"351_CR10","doi-asserted-by":"crossref","unstructured":"Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia. 2015. doi: 10.1111\/epi.13095 [Epub ahead of print].","DOI":"10.1111\/epi.13095"},{"key":"351_CR11","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","volume":"51","author":"MP Canevini","year":"2010","unstructured":"Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, Muscas G, La Neve A, Striano P, Perucca E, SOPHIE Study Group. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drud load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia. 2010;51:797\u2013804.","journal-title":"Epilepsia"},{"key":"351_CR12","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1528-1167.2011.03025.x","volume":"52","author":"S Chaluvad","year":"2011","unstructured":"Chaluvad S, Chiang S, Tran L, Goldsmith CE, Friedman D. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia. 2011;52:810\u20135.","journal-title":"Epilepsia"},{"key":"351_CR13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","volume":"48","author":"F Anderman","year":"2007","unstructured":"Anderman F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464\u20139.","journal-title":"Epilepsia"},{"key":"351_CR14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2147\/NDT.S2937","volume":"4","author":"B Abou-Khalil","year":"2008","unstructured":"Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4:507\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"351_CR15","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1345\/aph.1P765","volume":"45","author":"CL Fitzgerald","year":"2011","unstructured":"Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. Ann Pharmacother. 2011;45(5):e27. doi: 10.1345\/aph.1P765 [Epub 2011 Apr 26].","journal-title":"Ann Pharmacother"},{"issue":"1\u20132","key":"351_CR16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.eplepsyres.2011.03.014","volume":"95","author":"RE Bautista","year":"2011","unstructured":"Bautista RE, Gonzales W, Jain D. Factors associated with poor seizure control and increased side effects after switching to generic antiepileptic drugs. Epilepsy Res. 2011;95(1\u20132):158\u201367.","journal-title":"Epilepsy Res"},{"issue":"7","key":"351_CR17","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1528-1167.2011.03130.x","volume":"52","author":"SC Erickson","year":"2011","unstructured":"Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, et al. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia. 2011;52(7):1365\u201371.","journal-title":"Epilepsia"},{"issue":"Suppl 5","key":"351_CR18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1528-1167.2006.00871.x","volume":"47","author":"E Perucca","year":"2006","unstructured":"Perucca E, Albani F, Capovilla G, et al. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs. Epilepsia. 2006;47(Suppl 5):16\u201320.","journal-title":"Epilepsia"},{"key":"351_CR19","unstructured":"French Chapter of the International League Against Epilepsy (LFCE). Recommendations on the use of generics for the treatment of epilepsy [cited 2009 September 18]. http:\/\/www.ilae-epilepsy.org . Accessed 18 Feb 2010."},{"key":"351_CR20","first-page":"173","volume":"14","author":"S Striano","year":"2008","unstructured":"Striano S, Striano P, Capone D, Pisani F. Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med Sci Monit. 2008;14:173\u20138.","journal-title":"Med Sci Monit"},{"key":"351_CR21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.yebeh.2009.05.019","volume":"15","author":"RN Hansen","year":"2009","unstructured":"Hansen RN, Campbell JD, Sullivan SD. Association between antiepileptic drug switching and epilepsy-related events. Epilepsy Behav. 2009;15:481\u20135.","journal-title":"Epilepsy Behav"},{"key":"351_CR22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","volume":"51","author":"M Bialer","year":"2010","unstructured":"Bialer M, Midha KK. Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. Epilepsia. 2010;51:941\u201350.","journal-title":"Epilepsia"},{"key":"351_CR23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/YIC.0b013e328337910b","volume":"25","author":"HC Margolese","year":"2010","unstructured":"Margolese HC, Wolf Y, Desmarais JE, Beauclair L. Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol. 2010;25:180\u20132.","journal-title":"Int Clin Psychopharmacol"},{"issue":"Pt A","key":"351_CR24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yebeh.2015.08.014","volume":"52","author":"JJ Gagne","year":"2015","unstructured":"Gagne JJ, Kesselheim AS, Choudhry NK, Polinski JM, Hutchins D, Matlin OS, Brennan TA, et al. Comparative effectiveness of generic versus brand-name antiepileptic medications. Epilepsy Behav. 2015;52(Pt A):14\u20138. doi: 10.1016\/j.yebeh.2015.08.014 [Epub ahead of print].","journal-title":"Epilepsy Behav"},{"key":"351_CR25","doi-asserted-by":"crossref","unstructured":"Italiano D, Bruno A, Santoro V, Lanza G, Muscatello MR, Zoccali R, Spina E. Generic olanzepine substitution in patients with schizophrenia: assessment of serum concentrations and therapeutic response after switching. Ther Drug Monit. 2015. doi: 10.1097\/FTD.0000000000000211 .","DOI":"10.1097\/FTD.0000000000000211"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0351-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-015-0351-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-015-0351-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:28:56Z","timestamp":1559489336000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-015-0351-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["351"],"URL":"https:\/\/doi.org\/10.1007\/s40261-015-0351-1","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,27]]}}}